Breaking Down Clene: 4 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Clene Inc (NASDAQ:CLNN) has been analyzed by 4 analysts, showing unanimous bullish sentiment with a consistent 12-month price target of $7.00. The company, a clinical-stage pharmaceutical firm focusing on neurodegenerative diseases, has seen a -37.93% decline in revenue growth but outperforms in net margin and ROE compared to its peers. Despite challenges like a high debt-to-equity ratio, Clene's financial health appears strong.
March 13, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene Inc (NASDAQ:CLNN) receives unanimous bullish sentiment from analysts with a stable 12-month price target of $7.00, despite a significant revenue decline.
The unanimous bullish sentiment from analysts, coupled with a stable price target, suggests confidence in Clene's potential. Despite the revenue decline, strong net margin and ROE indicate efficient management and financial health, which could attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100